QuidelOrtho Corporation (QDEL)
NASDAQ: QDELHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
QDEL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $570.86M
- Forward P/E
- 6.32
- EPS (TTM)
- -$5.39
- Dividend yield
- None
- 52-week range
- 8.06 – 35.58
- Day range
- 8.06 – 8.95
- Volume / Avg
- 2.61M / 2.04M
- Beta
- —
- Shares outstanding
- 68.61M
52-week range
QDEL stock today
On Nov 20, QDEL ended the session at $8.32, shedding $0.60 (6.73%), versus the S&P 500's 3.70% decline. At this level, QDEL sits near the bottom of its 52-week range of $8.06 to $35.58: 76.6% below the high, set on Jan 16, 2026 and 3.2% above the low. QDEL is down 70.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 65.8%.
QuidelOrtho has posted a net loss over the last twelve months (EPS of -$5.39), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About QuidelOrtho
Company profileQuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Mr. Brian J. Blaser
- Headquarters
- San Diego, CA
- Employees
- 6,500
- Website
- quidelortho.com
Financial highlights
Full financialsIn fiscal 2025, QuidelOrtho generated $2.73 billion in revenue, down 1.9% from fiscal 2024, its first annual decline since 2024. QuidelOrtho reported a net loss of $1.13 billion, compared with a loss of $2.05 billion a year earlier. Gross margin was 46.7% (up from 46.2%) and operating margin -33.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $2.73B | $2.78B | $3.00B | $3.27B | $1.70B |
| Growth | -1.89% | -7.17% | -8.21% | +92.28% | +2.22% |
| Net income | $-1.13B | $-2.05B | $-10.10M | $548.70M | $704.20M |
| EPS (diluted) | $-16.69 | $-30.54 | $-0.15 | $9.56 | $16.43 |
Analyst forecast
ForecastConsensus (3 analysts)
hold
Avg. price target
$15.00+80.29%
- Strong buy 0
- Buy 1
- Hold 1
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $0.80 vs $0.18
- Surprise
- +344.44%
QDEL news
All QDEL news- QuidelOrtho Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of QuidelOrtho Corporation - QDELPR Newswire
- QuidelOrtho (QDEL) Securities Investigation Notice - Levi & KorsinskyPR Newswire
- QuidelOrtho Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into QuidelOrtho (QDEL)PR Newswire
- QuidelOrtho expects over $80M in 2027 annual savings as it narrows 2026 revenue to $2.52B-$2.54BSeeking Alpha
- QuidelOrtho launches restructuring program, eliminates COO roleSeeking Alpha
- QuidelOrtho Reports Third Quarter 2026 Financial ResultsPR Newswire
- Transforming Data Into Actionable Insights in the LabPR Newswire
- QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
QuidelOrtho peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| QUITAchieve Life Sciences Inc. | 5.56 | -5.28% | $573.25M | vs QDEL |
| MYGNMyriad Genetics Inc. | 5.46 | -1.44% | $523.74M | vs QDEL |
| TKNOAlpha Teknova Inc. | 7.63 | -2.30% | $479.95M | vs QDEL |
| NNNNAnbio Biotechnology Class A | 3.32 | -9.04% | $145.72M | vs QDEL |
| ICCCImmuCell Corporation | 10.92 | -2.41% | $99.28M | vs QDEL |
| IMDXInsight Molecular Diagnostics Inc. | 1.97 | +18.67% | $80.88M | vs QDEL |
| VNRXVolitionRX Limited | 0.1621 | -1.58% | $5.85M | vs QDEL |
| TRIBTrinity Biotech plc ADR | 6.24 | +13.76% | $5.07M | vs QDEL |
Indexes, lists and sector
QuidelOrtho stock FAQ
What is QuidelOrtho's stock price today?
QDEL last traded at $8.32 as of Nov 20, 4:00 PM EST, down 6.73% on the day. Prices are delayed at least 15 minutes.
Who is QuidelOrtho's CEO?
Mr. Brian J. Blaser is the chief executive officer of QuidelOrtho Corporation, which has about 6,500 employees.
What is the QDEL 52-week high?
The 52-week high for QDEL is $35.58 and the 52-week low is $8.06. The stock is currently 76.6% below its high.